Next Article in Journal
Simpson’s Paradox in Clinical Research: A Cautionary Tale
Previous Article in Journal
Psychometric Calibration of a Tool Based on 360 Degree Videos for the Assessment of Executive Functions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 4
10.3390/jcm12041646
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target

by
Han Li
1,†,
Ying Tang
2,†,
Lichun Hua
2,†,
Zemin Wang
1,
Guoping Du
3,
Shuai Wang
1,
Shifeng Lu
4,* and
Wei Li
5,*
1
Key Laboratory of Environmental Medicine Engineering, Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China
2
Department of Ultrasound Diagnostic, Children’s Hospital of Nanjing Medical University, Nanjing 210008, China
3
Department of General Practice, Southeast University Hospital, Nanjing 210018, China
4
Department of Hematology and Oncology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, China
5
Department of Clinical Research, Children’s Hospital of Nanjing Medical University, Nanjing 210008, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2023, 12(4), 1646; https://doi.org/10.3390/jcm12041646
Submission received: 20 January 2023 / Accepted: 13 February 2023 / Published: 18 February 2023
(This article belongs to the Section Oncology)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: We intended to explore the potential immunological functions and prognostic value of Myeloid Ecotropic Viral Integration Site 1 (MEIS1) across 33 cancer types. Methods: The data were acquired from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Gene expression omnibus (GEO) datasets. Bioinformatics was used to excavate the potential mechanisms of MEIS1 across different cancers. Results: MEIS1 was downregulated in most tumors, and it was linked to the immune infiltration level of cancer patients. MEIS1 expression was different in various immune subtypes including C2 (IFN-gamma dominant), C5 (immunologically quiet), C3 (inflammatory), C4 (lymphocyte depleted), C6 (TGF-b dominant) and C1 (wound healing) in various cancers. MEIS1 expression was correlated with Macrophages_M2, CD8+T cells, Macrophages_M1, Macrophages_M0 and neutrophils in many cancers. MEIS1 expression was negatively related to tumor mutational burden (TMB), microsatellite instability (MSI) and neoantigen (NEO) in several cancers. Low MEIS1 expression predicts poor overall survival (OS) in adrenocortical carcinoma (ACC), head and neck squamous cell carcinoma (HNSC), and kidney renal clear cell carcinoma (KIRC) patients, while high MEIS1 expression predicts poor OS in colon adenocarcinoma (COAD) and low grade glioma (LGG) patients. Conclusion: Our findings revealed that MEIS1 is likely to be a potential new target for immuno-oncology.

1. Introduction

Cancer is a disease that seriously affects human health, and it is also the most concerning disease by global research [1]. Globally, 18.1 million cases of cancer were newly diagnosed in 2020, and this number is expected to be 28.4 million in 2040; with the burden growing in almost every country, the prevention and treatment of cancer are significant public health challenges [2]. Currently, cancer treatment approaches primarily include chemotherapy, radiotherapy, surgery, targeted therapy, stem cell transplants, and immunotherapy [3,4]. Recently, immunotherapy has shown positive outcomes in various cancer types previously limited due to lack of known intervention strategies [5]. Immunotherapy is a form of cancer therapy that helps human to fight cancer by activating the immune system, which is assuredly one of the greatest innovation in cancer treatment in the last decade [6]. Biomarkers are important for predicting the outcomes in response to immunotherapy, numerous candidate biomarkers have been used; however, responses are only typically present in a small number of patients [7]. Novel immunotherapy targets can be screened by conducting pan-cancer analysis of genes in human tumors [8], including those that characterize the tumor microenvironment and targeted signaling pathways [9].
MEIS proteins, which belong to the three amino acid loop extension (TALE) class of transcription factor family, whose members include MEIS1 (NC_000002.12, Figure S1), MEIS2, and MEIS3 [10]. MEIS1 was first described in a leukemia mouse model. According to the single cell type module of Human Protein Atlas (http://www.proteinatlas.org/, accessed on 12 January 2023), MEIS1 expression is specificity to oligodendrocytes, rod photoreceptor cells, and endometrial stromal cells (Figure S2a). Meanwhile, in different blood and immune cells, the expression of MEIS1 was higher in total peripheral blood mononuclear cells (PBMC), natural killer (NK)-cells, and plasmacytoid dendritic cells (DC) (Figure S2b).
The expression of MEIS1 was influenced by cell types, age, the environment humans stay in, their pathological state, and the metabolism features of cancer cells [10,11]. MEIS1 was engaged in numerous cellular processes including chromatin remodeling, cell cycle regulation, apoptosis, and transcription regulation of self-renewal genes [12]. Research has shown that MEIS1 was strongly related to HOX genes and their cofactors to exert its regulatory effects on numerous signaling pathways [13]. Moreover, MEIS1 was a directly repressed target of MYC, and via effects on HOXB13, links MYC activity to androgen receptor activity to mediate cancer development [14]. MEIS1 can promote leukemogenesis and supports leukemic cell homing and engraftment by inducing synaptotagmin-like 1 (SYTL1) [15]. The impaired expression of MEIS1 was highly correlated with the poor prognosis of colorectal cancer patients [16]. In addition, MEIS1 was identified to reduce major histocompatibility complex class II (MHCII)expression in acute myeloid leukemia (AML) cells [17]), MEIS1 overexpression improved survival in patients with AML [18].
As a transcription factor, MEIS1 drives cell growth [19], dysregulated MEIS1 expression contributes to tumorigenesis in multiple tumor types [12,20,21,22,23]. Due to its role in cancer cell proliferation, MEIS1 can become a molecular biomarker for cancer diagnosis and even a target for cancer therapy [24]. However, the expression levels of MEIS1 in various tumors are different [10,24]. It is a negative regulator in non-small-cell lung cancer (NSCLC) [25], whereas it serves as a positive regulator in esophageal squamous cell carcinoma (ESCC) [26], malignant peripheral nerve sheath tumor (MPNST) [19] and Ewing sarcoma [27]. Even different studies found inconsistent expression of MEIS1 in prostate cancer [28,29]. The function of MEIS1 in cancer needs reassessing, we speculated that the oncogenic role of MEIS1 was affected by multiple factors, and it is possible that the complex role of MEIS1 in proliferation may largely depend on the tumor microenvironment (TME) [30]; nevertheless, the function of MEIS1 in TME remains uncertain. Various online tools were used to analyze the data from TCGA, GTEx and GEO databases, which intended to explore the potential mechanisms of MEIS1 across different cancers.

2. Materials and Methods

2.1. The Analysis of MEIS1 Expression in Different Cancers

MEIS1 gene differential expression between tumor tissues and normal tissues in 33 tumor types was explored in Gene_DE module of Tumor Immune Estimation Resource 2.0 (TIMER 2.0) [31]. Concerning many tumors without control data in TIMER 2.0, the Gene Expression Profile module of Gene Expression Profiling Interactive Analysis version 2 (GEPIA2) was used to match TCGA with GTEx data [32]. The differential expression analysis method was ANOVA and log2 (TPM + 1) for log-scale was used (we set |Log2FC| Cutoff as 1 with q-value Cutoff of 0.01) for box plots. “Stage Plots” in GEPIA2 can present MEIS1 gene expression in different stages in 26 tumor types. Log2(TPM + 1) for log-scale was used for violin plots.
The University of Alabama at Birmingham Cancer (UALCAN) data analysis Portal was used to analyze MEIS1 protein expression, phosphoprotein level and promoter methylation [33]. Breast cancer, clear cell renal cell carcinoma (ccRCC), colon cancer, lung adenocarcinoma (LUAD), ovarian cancer, and uterine corpus endometrial carcinoma (UCEC) were available for total-protein, phosphorylation and promoter methylation level analyses.

2.2. Association of MEIS1 with Survival in Different Tumors

In GEPIA2, the “Survival Analysis” module was used to reveal OS and disease-free survival (DFS) curves using the Kaplan–Meier method for the high and low MEIS1 expression groups in different cancer types. High and low expression groups were classified according to a 50% (median) cutoff of MEIS1 expression, and the hypothesis test method was the log-rank test.

2.3. Gene Alteration and Immune Infiltration Analysis of MEIS1

cBioPortal (https://www.cbioportal.org/, accessed on 28 September 2022) was equipped with the function to analyze gene alteration frequency, alteration types (mutation, amplification, multiple alterations), and mutation sites. The expression of MEIS1 in 22 tumor-infiltrating immune cells (TIICs) was evaluated by CIBERSORT on the SangerBox website (http://sangerbox.com/Tool, accessed on 28 September 2022). Meanwhile, the relationship between the expression of MEIS1 and immune checkpoint genes (ICPGs), TME biomarkers including TMB, MSI, and NEO were also explored. Furthermore, the relevance between MEIS1 expression and immune subtypes of 30 tumor types and molecular subtypes of 17 tumor types were analyzed utilizing the TISIDB database (http://cis.hku.hk/TISIDB/index.php, accessed on 28 September 2022).

2.4. Gene Enrichment Analysis of MEIS1

Firstly, the top-50 proteins binding with MEISI1 were obtained in STRING (https://string-db.org/, accessed on 7 October 2022) by setting “the minimum required interaction score”, “the meaning of network edges”, “active interaction sources” and “the max number of interactors to show” to “Low confidence”, “Evidence”, “Experiments” and “No more than 50 interactors”, respectively. The top-50 MEIS1-binding genes network was also presented.
The “Similar Gene Detection” module of GEPIA2 was used to detect 100 similar genes to MEIS1. In addition, the first five genes correlated with MEIS1 were selected according to Pearson’s correlation coefficients using the “Correlation Analysis” module of GEPIA2.
VENNY2.1 (https://bioinfogp.cnb.csic.es/tools/venny/index.html, accessed on 7 October 2022) was used to compare interacted genes with similar genes. GO and KEGG analysis was performed on 147 genes in two sets. “org.Hs.eg.db” package was applied to ID transform and the “clusterProfiler” package was applied to enrichment analysis. Data visualization was achieved through the “ggplot2” packages. This analysis was realized by R software [R-4.1.0, 64-bit, Vienna, Austria].

2.5. Ethical Approval

Our study was conducted in accordance with the principles stated in the Declaration of Helsinki, the secondary analysis of existing data of public use data sets does not require informed consent and ethical approval.

3. Results

3.1. Differential Expression of MEIS1 in Cancers

The result of MEIS1 expression in different cancers by the TIMER2.0 webserver was shown in Figure 1a, MEIS1 was down-regulated (the gene expression in the tumor group was lower than that in the control group) in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), COAD, HNSC, kidney renal papillary cell carcinoma (KIRP), LUAD, lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), thyroid carcinoma (THCA) and uterine corpus endometrial carcinoma (UCEC) (p < 0.001), pheochromocytoma and paraganglioma (PCPG) (p < 0.01), stomach adenocarcinoma (STAD), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) (p < 0.05). MEIS1 expression in tumor tissues of cholangiocarcinoma (CHOL), Liver hepatocellular carcinoma (LIHC) (p < 0.001) and glioblastoma multiforme (GBM) (p < 0.05) was higher than normal tissues.
For those tumors without control tissues in TIMER 2.0 datasets, GEPIA2 was used to match these tumor tissues with the control tissues in the GTEx database to obtain boxplots of expression differences. As shown in Figure 1b (p < 0.05), MEIS1 was differentially expressed in ACC, acute myeloid leukemia (LAML), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), thymoma (THYM) and uterine carcinosarcoma (UCS), which was down-regulated in ACC, SKCM, TGCT and UCS, and up-regulated in LAML and THYM. Furthermore, the statistically significant results were verified through GEO database. These results were presented in Figure S3, which were consistent with the results of MEIS1 differential expression analysis using the TCGA and GTEx database. MEIS1 protein expression in six common tumors was executed utilizing the CPTAC dataset. Figure 1c showed the total MEIS1 protein expression in breast cancer, colon cancer, LUAD, UCEC and ccRCC was higher than that in normal tissues (p < 0.001). Figure 1d revealed the correlation between pathological stages and MEIS1 expression levels, including ACC, COAD, KIRC, KIRP, and LIHC (p < 0.05). The correlation between pathological stages and MEIS1 expression levels in other cancer types with no statistical significance were shown in Figure S4.

3.2. Prognostic Index of MEIS1 in Different Cancers

As shown in Figure 2a, GEPIA2 survival analysis showed that low MEIS1 expression predicts poor OS of ACC, HNSC and KIRC patients (p < 0.01), while high MEIS1 expression predicts poor OS of COAD patients (p < 0.05) and LGG patients (p < 0.001). As shown in Figure 2b, high MEIS1 expression predicts poor DFS of COAD and KIRP patients (p < 0.01), and LGG patients (p < 0.001), while low MEIS1 expression predicts poor DFS of HNSC patients (p < 0.05).

3.3. Alteration of MEIS1 Gene Analysis Data

According to Figure 3a, in NSCLC, the frequency of gene change was the highest (3.51%) and mutation is the main type of gene change. Mutation is the main type of genetic change in ESCC, melanoma, endometrial carcinoma, esophagogastric adenocarcinoma, colorectal cancer, cervical squamous cell carcinoma, adrenal cortical cancer and hepatocellular carcinoma as well. Likewise, amplification became the primary type of MEIS1 gene alteration in ovarian epithelial tumor, bladder urothelial carcinoma, mature B-cell neoplasms and prostate adenocarcinoma. Furthermore, Figure 3b contains more details, such as mutation types, sites and the number of cases with “Missense” as the main type of mutation. R102Afs*20 mutation can be observed in 2 COAD patients while R102Pfs*18 can be detected in a UCEC patient. We did not find any hotspot mutation in the MEIS1 gene.

3.4. Phosphorylation and Promoter Methylation Expression of MEIS1 across Different Cancers

Changes in phosphorylation pathway are closely related to cancer. Based on the CPTAC dataset, breast cancer, ovarian cancer, colon cancer, ccRCC, UCEC, LUAD and pediatric brain cancer were included to explore phosphorylation level between their tumor tissues and normal tissues. Ultimately, the box plots of four types of cancer are available in Figure 4a. In ovarian cancer, MEIS1 phosphoprotein level (S194, S196 and T202) between tumor and normal tissues has no statistical differences, while the phosphorylation level of S196 in LUAD (p < 0.001), ccRCC (p < 0.001) and UCEC (p < 0.001) were higher in normal tissues compared to tumor tissues. More experiments evidence is needed to identify the function of MEIS1 phosphorylation at the S196 site in tumorigenesis. In addition, it is found that promoter methylation level of MEIS1 in BLCA, HNSC, KIRC, KIRP, PRAD and UCEC were lower in primary tumors compared to normal tissues (p < 0.05) (Figure 4b).

3.5. MEIS1 Expression in Immune and Molecular Subtypes across Different Cancers

As shown in Figure 5a, the expressions of MEIS1 were different in various immune subtypes including C1-C6 in ACC, BLCA, BRCA, CHOL, COAD, KIRC, LGG, LUAD, LUSC, pancreatic adenocarcinoma (PAAD), PRAD, sarcoma (SARC), STAD, TGCT (all p < 0.05). In addition, MEIS1 was diversely expressed in multiple molecular subtypes of ACC, BRCA, esophageal carcinoma (ESCA), GBM, HNSC, KIRP, LGG, LIHC, LUSC, ovarian serous cystadenocarcinoma (OV), PCPG, PRAD, STAD and UCEC (all p < 0.05) (Figure 5b).

3.6. MEIS1 Expression Is Related to ICPGs Expression in Different Cancers

Subsequently, the correlation between MEIS1 expression and 60 ICPGs expression was explored (Figure 6). In most cancers, such as lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), PRAD, READ, COAD, OV, KIRC and LIHC, MEIS1 expression was positively related to the expression of most ICPGs. It means that the patients with high expression of MEIS1 will show better immunotherapy effects by using immune checkpoint inhibitors (ICIs). However, in TCGT and SARC, MEIS1 expression was negatively correlated with most ICPGs expression. It showed that patients with high MEIS1 expression will have a poor prognosis when targeting these ICPGs. Therefore, it can be proved that MEIS1 is equipped with strong potential in immunotherapy.

3.7. The Correlation between MEIS1 Expression and Immune Cell Infiltration and TME in Different Cancers

According to results in Figure 7, MEIS1 expression was closely correlated with most immune cells in various cancers. The expression of MEIS1 was correlated with macrophages_M2 in 20 cancer types, CD8+T cells in 19 cancer types, Macrophages_M1 in 15 cancer types, macrophages_M0 in 13 cancer types and neutrophils in 10 cancer types. For evaluating anti-tumor immunity, as shown in Figure 8, the relationships between MEIS1 and TMB, MSI and NEO were explored in all cancers. MEIS1 expression was negatively associated with TMB in ACC, STAD, STES, SARC, BLCA and KIRC. As for MSI, MEIS1 expression was negatively correlated with MSI in UCS, UCEC, SARC, STAD, STES, GBM, LGG, KIPAN, PRAD and HNSC, while it was positively associated with MSI in TGCT. In addition, MEIS1 expression had a negative correlation with NEO in SARC, UCEC, KIRP, KIPAN, KIRC and LUAD.

3.8. MEIS1-Related Genes Are Correlated to Cell Proliferation and Differentiation

Based on STRING, 50 MEIS1-binding proteins supported by experiments were obtained. The protein–protein interaction networks are presented in Figure 9a. After that, 100 similar genes were acquired from correlation analysis in GEPIA2, 50 interacted genes and 100 similar genes have 3 overlap genes in Figure 9b. Then, the 147 genes were integrated to perform GO and KEGG analysis presented in Figure 9c. KEGG analysis indicates that “Transcriptional misregulation in cancer” might play a vital role in the effect of MEIS1 on cancers. Furthermore, by GO analysis, at the biological process (BP) level, most of the genes are involved in cell differentiation and cell fate determination. At the molecular function (MF) level, most of the genes took part in regulating DNA-binding transcription activator and repressor activity, RNA polymerase II-specific, enhancer sequence-specific and activating transcription factor binding. At last, the cellular component (CC) also proved that these genes were related to transcription.

4. Discussion

Cancer is a leading cause of death in each country, and the number of newly confirmed patients continues to increase [2]. Although current cancer therapy options exhibit some clinical success, a large number of cancer patients still have poor prognoses because of drug resistance, adverse effects, and other issues [34]. Consequently, there is a need to identify new therapeutic targets and sensitive biomarkers for cancer diagnosis and treatment. The pan-cancer analysis can deliver deep perception for the design of cancer prevention and precision treatment strategies by revealing the similarities and differences between different cancers [34]. In our study, we comprehensively performed MEIS1 expression and its correlation with prognostic and immunotherapy value in pan-cancer via different databases. The 33 cancer types were studied to identify MEIS1 expression in this study and it finally suggests that MEIS1 expression is different between tumor tissues and normal tissues in 23 cancer types. Among these 23 cancer types, MEIS1 expression is down-regulated in 18 cancer types, on the contrary, the other 5 types were up-regulated.
Another major finding is that MEIS1 expression correlates with survival in cancer patients, which indicated that the abnormal expression of MEIS1 can be responsible for the poor prognosis of tumors. For the value of MEIS1 on the prognosis of cancer patients, it could be determined by the activity of the MEIS1 protein which depends on the environment in which the cell exists. A similar finding was also demonstrated by Schulte et al. and Meng et al. by performing studies on MEIS1 [30,35]. MEIS1 is a hub gene in the differentially expressed gene interaction network for lung adenocarcinoma (LUAD) and participated in the occurrence and prognosis of LUAD [23]. MEIS1 overexpression was inversely correlated with relapse and overall survival in children with acute leukemias [36]. Down-regulated expression of MEIS1 was detected in colorectal cancer and predicted poor survival of colorectal cancer patients [16]. It is believed that abnormal DNA methylation plays a critical role in cancer development and progression [37]. Tumors and benign tissues exhibit different methylation patterns [38,39]. Our study found that the promoter methylation levels of MEIS1 in BLCA, HNSC, KIRC, KIRP, PRAD, and UCEC were lower in primary tumors compared to normal tissues. In conclusion, MEIS1 may be able to regulate some tumors at an epigenetic level, but more studies are needed to clarify the deeper mechanisms.
Immune infiltration is highly associated with the prognosis of tumor patients [40]. Six types of immune infiltration had been explored in cancer patients, maybe promoting or inhibiting tumor cell growth [41]. Among them, C5 is positively correlated to MEIS1. A high level of C5 can impair the curative effect of immune checkpoint inhibitors, as reported by Lehrer and his colleagues [42]. Our findings showed that MEIS1 expression was strongly related to most immune cells in various types of cancer. Moreover, MEIS1 expression is related to some immune subtypes and molecular subtypes in different types of cancer. We indicated that MEIS1 can play a role in the growth and progression of cancer and have a close correlation with immune regulation. The TMB, MSI, and NEO which characterize anti-tumor immunity were negatively related to MEIS1 expression in some cancers. Therefore, the immunotherapeutic effect of cancer patients can be predicted according to MEIS1 expression. It can contribute to guide immunotherapy more accurately. The MEIS1 expression was negatively related to TMB, MSI, and NEO in SARC. Thus, there is an inference that patients suffering from SARC with low MEIS1 expression might predicted better survival after immunotherapy. In most cancers, MEIS1 expression was positively related to most ICPGs expression. There is bold speculation that using immune checkpoint inhibitors along with interfering in MEIS expression will have an effective impact on the patient [30].
In gene enrichment analysis, HOXD4, HOXB4, and PBX2 were co-expressed with MEIS1. HOX were transcription factors that serve as an essential regulator for cell fate determination, stem cell functions, and gastrointestinal development. And they need TALE family proteins such as MEIS and PBX to improve their transcriptional efficiencies [43]. MEIS and PBX were correlated with cell growth, differentiation and apoptosis [44,45]. MEIS1 accompanied by HOX protein can form a complex to recruit transcriptional corepressors or coactivators [13]. Meanwhile, the activation of MEIS1 always couples with the activation of HOXA7 or HOXA9 [46]. Previous papers have summarized the impact of HOX genes on tumors and concluded that HOX genes take part in the development of different tumors [47]. There was research which found that MEIS1 and PBX2 overexpressed in nephroblastomas [48]. So, there may be interference with HOX genes and PBX genes during the role of MEIS1 in cancers. A further mechanism of MEIS1 for different tumors is needed, to explore in the future.
According to KEGG analysis in this study, “Transcriptional misregulation in cancer” might play a vital role in the effect of MEIS1 on cancers. As an important transcription factor, if MEIS1 is over-expressed or low-expressed, transcriptional misregulation will emerge and then play a role in cancer development [49]. Based on GO analysis, MEIS1 may take part in tumor development by regulating cell differentiation and “DNA-binding transcription activator and repressor activity”, “RNA polymerase II-specific”, “enhancer sequence-specific” and “activating transcription factor binding”. Several researches have shown that MEIS1 serves as a tumor suppressor in ccRCC [50], prostate [29], NSCLC [25], gastric [51], and colorectal cancers [52] by promoting cell differentiation and inhibiting epithelial cell proliferation.

5. Conclusions

To sum up, our findings offer a comprehensive understanding of the functions of MEIS1 in prognostic and immunotherapy in different types of cancer. MEIS1 has the potential as a cancer immunotherapy target and is worthy of more attention. Moreover, our results may provide valuable theoretical guidance for further research on the mechanism of MEIS1 in vivo and in vitro.

6. Limitations

This research had some restrictions. Initially, we only performed a series of bioinformatics analysis of MEIS1 in multiple databases, the mechanisms of MEIS1 in different cancer types were not verified. Secondly, the small samples for some tumor types may cause inaccurate results or bias.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/jcm12041646/s1, Figure S1: The Genomic context of MEIS1, Figure S2: The specificity expression of MEIS1 in single cell. (a) The single cell type specificity expression of MEIS1. (b) The specificity expression of MEIS1 in blood and immune cells. Figure S3: MEIS1 gene expression level in 16 tumor tissues and normal tissues in GEO database. **** p < 0.0001; ** p < 0.01; * p < 0.05. Figure S4: MEIS1 expression level in different pathological stages of THCA, BRCA, CESC, UCEC, DLBC, ESCA, HNSC, kidney chromophobe (KICH), LUAD, LUSC, UCS, PAAD, READ, SKCM, STAD, TGCT, BLCA, CHOL, and OV (p > 0.05).

Author Contributions

W.L.: conceptualization, writing—original draft preparation. H.L.: methodology, formal analysis. Y.T.: formal analysis. Z.W. and G.D.: software, validation. S.W.: data curation. L.H.: writing—reviewing and editing. S.L.: conceptualization, funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

The study will be financed by China Postdoctoral Science Foundation (2022M721682) and the Medical Scientific Research Project of Jiangsu Provincial Health Commission (ZD2022053).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article.

Conflicts of Interest

The authors declare no competing interests.

References

  1. Mao, Y.; Huang, Y.; Gao, L. Current situation of immuno-oncology development. Sci. Technol. Rev. 2017, 35, 61–65. [Google Scholar]
  2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
  3. Debela, D.T.; Muzazu, S.G.; Heraro, K.D.; Ndalama, M.T.; Mesele, B.W.; Haile, D.C.; Kitui, S.K.; Manyazewal, T. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021, 9, 20503121211034366. [Google Scholar] [CrossRef] [PubMed]
  4. National Cancer Institute. Types of Cancer Treatment. Available online: https://www.cancer.gov/about-cancer/treatment/types (accessed on 19 January 2023).
  5. De Miguel, M.; Calvo, E. Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell 2020, 38, 326–333. [Google Scholar] [CrossRef] [PubMed]
  6. Li, Y.; Veeraraghavan, J.; Philip, R. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective. Methods Mol. Biol. 2020, 2055, 701–716. [Google Scholar]
  7. Masucci, G.V.; Cesano, A.; Hawtin, R.; Janetzki, S.; Zhang, J.; Kirsch, I.; Dobbin, K.K.; Alvarez, J.; Robbins, P.B.; Selvan, S.R.; et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I—Pre-analytical and analytical validation. J. Immunother. Cancer 2016, 4, 76. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Cheng, X.; Wang, X.; Nie, K.; Cheng, L.; Zhang, Z.; Hu, Y.; Peng, W. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Front. Immunol. 2021, 12, 646523. [Google Scholar] [CrossRef]
  9. Jain, K.K. Personalized Immuno-Oncology. Med. Princ. Pract. 2021, 30, 1–16. [Google Scholar] [CrossRef]
  10. Jiang, M.; Xu, S.; Bai, M.; Zhang, A. The emerging role of MEIS1 in cell proliferation and differentiation. Am. J. Physiol. Cell Physiol. 2021, 320, C264–C269. [Google Scholar] [CrossRef]
  11. Aksoz, M.; Turan, R.D.; Albayrak, E.; Kocabas, F. Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer. Curr. Drug Targets 2018, 19, 181–190. [Google Scholar] [CrossRef]
  12. Zargari, S.; Negahban Khameneh, S.; Rad, A.; Forghanifard, M.M. MEIS1 promotes expression of stem cell markers in esophageal squamous cell carcinoma. BMC Cancer 2020, 20, 789. [Google Scholar] [CrossRef]
  13. Paul, S.; Zhang, X.; He, J.Q. Homeobox gene Meis1 modulates cardiovascular regeneration. Semin. Cell Dev. Biol. 2020, 100, 52–61. [Google Scholar] [CrossRef]
  14. Whitlock, N.C.; Trostel, S.Y.; Wilkinson, S.; Terrigino, N.T.; Hennigan, S.T.; Lake, R.; Carrabba, N.V.; Atway, R.; Walton, E.D.; Gryder, B.E.; et al. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. Oncogene 2020, 39, 5663–5674. [Google Scholar] [CrossRef]
  15. Yokoyama, T.; Nakatake, M.; Kuwata, T.; Couzinet, A.; Goitsuka, R.; Tsutsumi, S.; Aburatani, H.; Valk, P.J.; Delwel, R.; Nakamura, T. MEIS1-mediated transactivation of synaptotagmin-like, 1 promotes CXCL12/CXCR4 signaling and leukemogenesis. J. Clin. Invest. 2016, 126, 1664–1678. [Google Scholar] [CrossRef] [Green Version]
  16. Li, Y.; Gan, Y.; Liu, J.; Li, J.; Zhou, Z.; Tian, R.; Sun, R.; Liu, J.; Xiao, Q.; Li, Y.; et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct. Target. Ther. 2022, 7, 87. [Google Scholar] [CrossRef]
  17. Eagle, K.; Harada, T.; Kalfon, J.; Perez, M.W.; Heshmati, Y.; Ewers, J.; Koren, J.V.; Dempster, J.M.; Kugener, G.; Paralkar, V.R.; et al. Transcriptional Plasticity Drives Leukemia Immune Escape. Blood Cancer Discov. 2022, 3, 394–409. [Google Scholar] [CrossRef]
  18. Walker, A.R.; Byrd, J.C.; Blachly, J.S.; Bhatnagar, B.; Mims, A.S.; Orwick, S.; Lin, T.L.; Crosswell, H.E.; Zhang, D.; Minden, M.D.; et al. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clin. Cancer Res. 2020, 26, 5852–5859. [Google Scholar] [CrossRef] [PubMed]
  19. Patel, A.V.; Chaney, K.E.; Choi, K.; Largaespada, D.A.; Kumar, A.R.; Ratner, N. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors. EBioMedicine 2016, 9, 110–119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Ferreira, H.J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martínez-Cardús, A.; Simó-Riudalbas, L.; Moran, S.; Jost, E.; et al. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia. Oncogene 2017, 36, 4233. [Google Scholar] [CrossRef] [Green Version]
  21. Geerts, D.; Schilderink, N.; Jorritsma, G.; Versteeg, R. The role of the MEIS homeobox genes in neuroblastoma. Cancer Lett. 2003, 197, 87–92. [Google Scholar] [CrossRef] [PubMed]
  22. Okumura, K.; Saito, M.; Isogai, E.; Aoto, Y.; Hachiya, T.; Sakakibara, Y.; Katsuragi, Y.; Hirose, S.; Kominami, R.; Goitsuka, R.; et al. Meis1 regulates epidermal stem cells and is required for skin tumorigenesis. PLoS ONE 2014, 9, e102111. [Google Scholar] [CrossRef]
  23. Wang, Z.; Li, X.; Chen, H.; Han, L.; Ji, X.; Wang, Q.; Wei, L.; Miao, Y.; Wang, J.; Mao, J.; et al. Decreased HLF Expression Predicts Poor Survival in Lung Adenocarcinoma. Med. Sci. Monit. 2021, 27, e929333. [Google Scholar] [CrossRef] [PubMed]
  24. Yao, M.; Gu, Y.; Yang, Z.; Zhong, K.; Chen, Z. MEIS1 and its potential as a cancer therapeutic target. Int. J. Mol. Med. 2021, 48, 181. [Google Scholar] [CrossRef] [PubMed]
  25. Li, W.; Huang, K.; Guo, H.; Cui, G. Meis1 regulates proliferation of non-small-cell lung cancer cells. J. Thorac. Dis. 2014, 6, 850–855. [Google Scholar] [PubMed]
  26. Rad, A.; Farshchian, M.; Forghanifard, M.M.; Matin, M.M.; Bahrami, A.R.; Geerts, D.; A’rabi, A.; Memar, B.; Abbaszadegan, M.R. Predicting the molecular role of MEIS1 in esophageal squamous cell carcinoma. Tumour. Biol. 2016, 37, 1715–1725. [Google Scholar] [CrossRef] [PubMed]
  27. Lin, L.; Huang, M.; Shi, X.; Mayakonda, A.; Hu, K.; Jiang, Y.Y.; Guo, X.; Chen, L.; Pang, B.; Doan, N.; et al. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. Nucleic Acids Res. 2019, 47, 1255–1267. [Google Scholar] [CrossRef] [PubMed]
  28. Johng, D.; Torga, G.; Ewing, C.M.; Jin, K.; Norris, J.D.; Mcdonnell, D.P.; Isaacs, W.B. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. Prostate 2019, 79, 414–424. [Google Scholar] [CrossRef] [PubMed]
  29. Vanopstall, C.; Perike, S.; Brechka, H.; Gillard, M.; Lamperis, S.; Zhu, B.; Brown, R.; Bhanvadia, R.; Vander Griend, D.J. MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans. Elife 2020, 9, e53600. [Google Scholar] [CrossRef]
  30. Meng, L.; Tian, Z.; Wang, J.; Liu, X.; Zhang, W.; Hu, M.; Wang, M.; Zhang, Y. Effect of myeloid ecotropic viral integration site (MEIS) family genes on tumor microenvironment remodeling and its potential therapeutic effect. Transl. Androl. Urol. 2021, 10, 594–608. [Google Scholar] [CrossRef]
  31. Li, T.; Fu, J.; Zeng, Z.; Cohen, D.; Li, J.; Chen, Q.; Li, B.; Liu, X.S. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020, 48, W509–W514. [Google Scholar] [CrossRef]
  32. Tang, Z.; Kang, B.; Li, C.; Chen, T.; Zhang, Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019, 47, W556–W560. [Google Scholar] [CrossRef] [Green Version]
  33. Chandrashekar, D.S.; Karthikeyan, S.K.; Korla, P.K.; Patel, H.; Shovon, A.R.; Athar, M.; Netto, G.J.; Qin, Z.S.; Kumar, S.; Manne, U.; et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 2022, 25, 18–27. [Google Scholar] [CrossRef]
  34. Chen, F.; Fan, Y.; Cao, P.; Liu, B.; Hou, J.; Zhang, B.; Tan, K. Pan-Cancer Analysis of the Prognostic and Immunological Role of HSF1: A Potential Target for Survival and Immunotherapy. Oxid. Med. Cell. Longev. 2021, 2021, 5551036. [Google Scholar] [CrossRef]
  35. Schulte, D.; Geerts, D. MEIS transcription factors in development and disease. Development 2019, 146, dev174706. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Adamaki, M.; Lambrou, G.I.; Athanasiadou, A.; Vlahopoulos, S.; Papavassiliou, A.G.; Moschovi, M. HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival. Leuk. Res. 2015, 39, 874–882. [Google Scholar] [CrossRef] [PubMed]
  37. Wang, J.; Yang, J.; Li, D.; Li, J. Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer. Biochim. Biophys. Acta Rev. Cancer 2021, 1875, 188454. [Google Scholar] [CrossRef]
  38. Koch, A.; Joosten, S.C.; Feng, Z.; De Ruijter, T.C.; Draht, M.X.; Melotte, V.; Smits, K.M.; Veeck, J.; Herman, J.G.; Van Neste, L.; et al. Analysis of DNA methylation in cancer: Location revisited. Nat. Rev. Clin. Oncol. 2018, 15, 459–466. [Google Scholar] [CrossRef] [PubMed]
  39. Saghafinia, S.; Mina, M.; Riggi, N.; Hanahan, D.; Ciriello, G. Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors. Cell Rep. 2018, 25, 1066–1080.e8. [Google Scholar] [CrossRef] [Green Version]
  40. Bi, K.W.; Wei, X.G.; Qin, X.X.; Li, B. BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. Front. Oncol. 2020, 10, 424. [Google Scholar] [CrossRef] [Green Version]
  41. Tamborero, D.; Rubio-Perez, C.; Muiños, F.; Sabarinathan, R.; Piulats, J.M.; Muntasell, A.; Dienstmann, R.; Lopez-Bigas, N.; Gonzalez-Perez, A. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clin. Cancer Res. 2018, 24, 3717–3728. [Google Scholar] [CrossRef] [Green Version]
  42. Lehrer, S.; Rheinstein, P.H. Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer. Cancer Genom. Proteom. 2018, 15, 387–393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Moghbeli, M.; Rad, A.; Farshchian, M.; Taghehchian, N.; Gholamin, M.; Abbaszadegan, M.R. Correlation Between Meis1 and Msi1 in Esophageal Squamous Cell Carcinoma. J. Gastrointest. Cancer 2016, 47, 273–277. [Google Scholar] [CrossRef] [PubMed]
  44. Dimartino, J.F.; Selleri, L.; Traver, D.; Firpo, M.T.; Rhee, J.; Warnke, R.; O’gorman, S.; Weissman, I.L.; Cleary, M.L. The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver. Blood 2001, 98, 618–626. [Google Scholar] [CrossRef] [Green Version]
  45. Pillay, L.M.; Forrester, A.M.; Erickson, T.; Berman, J.N.; Waskiewicz, A.J. The Hox cofactors Meis1 and Pbx act upstream of gata1 to regulate primitive hematopoiesis. Dev. Biol. 2010, 340, 306–317. [Google Scholar] [CrossRef] [Green Version]
  46. Nakamura, T.; Largaespada, D.A.; Shaughnessy, J.D., Jr.; Jenkins, N.A.; Copeland, N.G. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat. Genet. 1996, 12, 149–153. [Google Scholar] [CrossRef] [PubMed]
  47. Bhatlekar, S.; Fields, J.Z.; Boman, B.M. HOX genes and their role in the development of human cancers. J. Mol. Med. 2014, 92, 811–823. [Google Scholar] [CrossRef]
  48. Koller, K.; Pichler, M.; Koch, K.; Zandl, M.; Stiegelbauer, V.; Leuschner, I.; Hoefler, G.; Guertl, B. Nephroblastomas show low expression of microR-204 and high expression of its target, the oncogenic transcription factor MEIS1. Pediatr. Dev. Pathol. 2014, 17, 169–175. [Google Scholar] [CrossRef]
  49. Bradner, J.E.; Hnisz, D.; Young, R.A. Transcriptional Addiction in Cancer. Cell 2017, 168, 629–643. [Google Scholar] [CrossRef] [Green Version]
  50. Zhu, J.; Cui, L.; Xu, A.; Yin, X.; Li, F.; Gao, J. MEIS1 inhibits clear cell renal cell carcinoma cells proliferation and in vitro invasion or migration. BMC Cancer 2017, 17, 176. [Google Scholar] [CrossRef] [Green Version]
  51. Song, F.; Wang, H.; Wang, Y. Myeloid ecotropic viral integration site, 1 inhibits cell proliferation, invasion or migration in human gastric cancer. Oncotarget 2017, 8, 90050–90060. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Crist, R.C.; Roth, J.J.; Waldman, S.A.; Buchberg, A.M. A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. PLoS ONE 2011, 6, e23665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Jcm 12 01646 g001 550
Figure 1. MEIS1gene and protein expression in 33 tumors and pathological stages of tumors. (a) MEIS1 gene expression level in 33 tumor tissues and normal tissues, even specific subtypes of tumors through TIMER2 (Blue represents normal tissues, red represents tumor tissues and purple represents metastatic tumors). *** p < 0.001; ** p < 0.01; * p < 0.05. (b) MEIS1 gene expression in tumors without normal tissues in TCGA, including ACC, LAML, SKCM, TGCT, THYM and UCS. * p < 0.05. (c) Total protein expression level of MEIS1 in tumor tissues and normal tissues of Breast cancer, Colon cancer, ccRCC, UCEC and LUAD. *** p < 0.001. (d) MEIS1 expression level in different pathological stages of ACC, COAD, KIRC, KIRP and LIHC.
Figure 1. MEIS1gene and protein expression in 33 tumors and pathological stages of tumors. (a) MEIS1 gene expression level in 33 tumor tissues and normal tissues, even specific subtypes of tumors through TIMER2 (Blue represents normal tissues, red represents tumor tissues and purple represents metastatic tumors). *** p < 0.001; ** p < 0.01; * p < 0.05. (b) MEIS1 gene expression in tumors without normal tissues in TCGA, including ACC, LAML, SKCM, TGCT, THYM and UCS. * p < 0.05. (c) Total protein expression level of MEIS1 in tumor tissues and normal tissues of Breast cancer, Colon cancer, ccRCC, UCEC and LUAD. *** p < 0.001. (d) MEIS1 expression level in different pathological stages of ACC, COAD, KIRC, KIRP and LIHC.
Jcm 12 01646 g001
Jcm 12 01646 g002 550
Figure 2. Correlation between MEIS1 expression and survival of patients of cancers in TCGA. The survival plots and Kaplan-Meier curves with positive outcomes were given. (a) Correlation between MEIS1 expression and OS of ACC, COAD, HNSC, KIRC, LGG and UVM patients. (b) Correlation between MEIS1 expression and DFS of COAD, HNSC, KIRP and LGG patients.
Figure 2. Correlation between MEIS1 expression and survival of patients of cancers in TCGA. The survival plots and Kaplan-Meier curves with positive outcomes were given. (a) Correlation between MEIS1 expression and OS of ACC, COAD, HNSC, KIRC, LGG and UVM patients. (b) Correlation between MEIS1 expression and DFS of COAD, HNSC, KIRP and LGG patients.
Jcm 12 01646 g002
Jcm 12 01646 g003 550
Figure 3. MEIS1 gene alteration frequency, types, sites and cases. (a) MEIS1 alteration types and frequency. (b) MEIS1 mutation types, sites and cases. “+” represents that data are available.
Figure 3. MEIS1 gene alteration frequency, types, sites and cases. (a) MEIS1 alteration types and frequency. (b) MEIS1 mutation types, sites and cases. “+” represents that data are available.
Jcm 12 01646 g003
Jcm 12 01646 g004 550
Figure 4. Phosphorylation and promoter methylation analyses of MEIS1 protein in different tumors. (a) Phosphorylation level of MEIS1 between their tumor tissues and normal tissues. (b) Promoter methylation level of MEIS1 between their tumor tissues and normal tissues.
Figure 4. Phosphorylation and promoter methylation analyses of MEIS1 protein in different tumors. (a) Phosphorylation level of MEIS1 between their tumor tissues and normal tissues. (b) Promoter methylation level of MEIS1 between their tumor tissues and normal tissues.
Jcm 12 01646 g004
Jcm 12 01646 g005 550
Figure 5. MEIS1 expression in immune and molecular subtypes of cancers (a) The relationship between MEIS1 expression and immune subtypes of cancers. (b) The relationship between MEIS1 expression and molecular subtypes of cancers.
Figure 5. MEIS1 expression in immune and molecular subtypes of cancers (a) The relationship between MEIS1 expression and immune subtypes of cancers. (b) The relationship between MEIS1 expression and molecular subtypes of cancers.
Jcm 12 01646 g005
Jcm 12 01646 g006 550
Figure 6. The correlation matrix between MEIS1 expression and ICPG expressions. * p < 0.05.
Figure 6. The correlation matrix between MEIS1 expression and ICPG expressions. * p < 0.05.
Jcm 12 01646 g006
Jcm 12 01646 g007 550
Figure 7. The correlation matrix between MEIS1 expression and immune cell content. * p < 0.05.
Figure 7. The correlation matrix between MEIS1 expression and immune cell content. * p < 0.05.
Jcm 12 01646 g007
Jcm 12 01646 g008 550
Figure 8. The relationship between MEIS1 expression and anti-immunity indicators (a) The relationship between MEIS1 expression and TMB (b) The relationship between MEIS1 expression and MSI. (c) The relationship between MEIS1 expression and NEO.
Figure 8. The relationship between MEIS1 expression and anti-immunity indicators (a) The relationship between MEIS1 expression and TMB (b) The relationship between MEIS1 expression and MSI. (c) The relationship between MEIS1 expression and NEO.
Jcm 12 01646 g008
Jcm 12 01646 g009 550
Figure 9. MEIS1-related genes’ enrichment analysis. (a) 50 MEIS1-binding proteins’ interaction network derived from STRING. (b) Venn diagram showing the intersection between MEIS1-interacted genes and MEISI-correlated genes. (c) Bubble diagram for GO and KEGG analysis of MEIS1-related genes.
Figure 9. MEIS1-related genes’ enrichment analysis. (a) 50 MEIS1-binding proteins’ interaction network derived from STRING. (b) Venn diagram showing the intersection between MEIS1-interacted genes and MEISI-correlated genes. (c) Bubble diagram for GO and KEGG analysis of MEIS1-related genes.
Jcm 12 01646 g009
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, H.; Tang, Y.; Hua, L.; Wang, Z.; Du, G.; Wang, S.; Lu, S.; Li, W. A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target. J. Clin. Med. 2023, 12, 1646. https://doi.org/10.3390/jcm12041646

AMA Style

Li H, Tang Y, Hua L, Wang Z, Du G, Wang S, Lu S, Li W. A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target. Journal of Clinical Medicine. 2023; 12(4):1646. https://doi.org/10.3390/jcm12041646

Chicago/Turabian Style

Li, Han, Ying Tang, Lichun Hua, Zemin Wang, Guoping Du, Shuai Wang, Shifeng Lu, and Wei Li. 2023. "A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target" Journal of Clinical Medicine 12, no. 4: 1646. https://doi.org/10.3390/jcm12041646

APA Style

Li, H., Tang, Y., Hua, L., Wang, Z., Du, G., Wang, S., Lu, S., & Li, W. (2023). A Systematic Pan-Cancer Analysis of MEIS1 in Human Tumors as Prognostic Biomarker and Immunotherapy Target. Journal of Clinical Medicine, 12(4), 1646. https://doi.org/10.3390/jcm12041646

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop